ClinicalTrials.gg
RecruitingNCT05857696GAITSTIMUpdated Jun 16, 2026

Improvement of Gait by Spinal Stimulation in Patients With Postoperative Chronic Lumbosciatalgia: Pilot Study (GaitStim)

An interventional study of walking quantified analysis in Failed Back Surgery Syndrome, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to explore the changes in objective walking parameters induced by medullary stimulation in patients with Fail Back Surgery Syndrome, after chronic stimulation, in comparison with preoperative condition.

Read the detailed description

After the informed consent signature, a first assessment will be carried out, including: quantified analysis of walking (AQM), felt effort questionnaire, pain questionnaires, functional abilities, limitations, goals and quality of life.

The implantation of the spinal cord stimulation system will be performed in two stages: the first stage, the electrode alone will be implanted and connected to an external test stimulator, allowing a one-week stimulation test.

If the test is positive (EVA pain improvement > or = 50%), the second step will be to connect this electrode to a Spectra WaveWriter™ internal stimulator. This stimulator delivers three different stimulation modalities: tonic, microburst and high frequency. The activated initial stimulation mode will be the tonic one.

After 3 months of "tonic" stimulation, the patient will be treated successively and in random way by 3 other different stimulation modalities during a week: microburst, high frequency, stopped stimulation (Off). The AQM and the different questionnaires will be done again, which will determine which stimulation modality is most beneficial to the patient.

02

Conditions studied

  • Failed Back Surgery Syndrome

Keywords

  • Spinal cord neurostimulation
  • chronic pain
03

In context

Failed Back Surgery Syndrome

104 studies on the registry are indexed under Failed Back Surgery Syndrome; 15 are open to participants now.

This study's planned enrollment of 36 is close to the median of 40 across 75 interventional studies indexed under Failed Back Surgery Syndrome.

Browse Failed Back Surgery Syndrome studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 year old and \< or = 70 year old
  • Patients with chronic neuropathic lumbo-sciatalgia (DN4 score > or = 4/10) as part of a moderate to severe spinal surgery failure syndrome (EVA >50/100), in who a collegial and multidisciplinary indication of medullary stimulation treatment was chosen.
  • Patients awith Social Security

Exclusion criteria

Exclusion Criteria:

  • Vulnerable persons
  • Patients who are invalid and unable to perform a quantified walk analysis
  • to surgery or anesthesia
  • Patient not able to complete questionnaires
  • Woman of childbearing age without effective
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    neurostimulation

    3 months of tonic stimutaltion + 3 weeks with random stimulation mode between microburst, High frequency, stopped stimulation (Off) then stimulation with the more efficient mode (according the patient) until 6 monthe after implantation.

    Other: walking quantified analysis

Interventions

  • Otherwalking quantified analysis

    Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.

06

What researchers measure

Primary outcomes

  1. To explore the changes in objective walking parameters induced by spinal stimulation in patients with FBSS, after 6 months of chronic stimulation, in comparison with preoperative status.

    Gait quantified analysis with Gait Deviation Index

    Time frame: At baseline, 3 and 6 months after implantation

Secondary outcomes

  1. To describe the gait alteration in a population of patients with FBSS

    Gait quantified analysis with Gait Deviation Index

    Time frame: At baseline, 3 and 6 months after implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Oct 2028, 56 months after the start.

Of 36 non-industry interventional studies with no phase under Failed Back Surgery Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 56 months is above that.

Counting every sponsor, half of 38 studies reached it within 23 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
May 12, 2023
StartActual
Feb 23, 2024
Primary completionEst.
Oct 23, 2028
CompletionEst.
Oct 23, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857696
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Feb 23, 2024
Primary completion
Oct 23, 2028 (estimated)
Completion
Oct 23, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

LE GOFF Ludovic, MD
Contact
legoff.l@chu-nice.fr
+334 92 03 55 07

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion